Nouscom

Nouscom company information, Employees & Contact Information

Explore related pages

Related company profiles:

Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high immunogenicity in patients. Nouscom’s clinical pipeline includes NOUS-209, an off-the-shelf cancer immunotherapy assessing the efficacy of the treatment in advanced MSI-H CRC patients in combination with pembrolizumab in randomized phase 2 trials. A Phase 1b study of NOUS-209 monotherapy in Lynch Syndrome Carriers with potential to ‘intercept cancer’ before it occurs is running in collaboration with the National Cancer Institute. Nouscom's second clinical program is NOUS-PEV, a personalized cancer immunotherapy for the treatment of advanced cancers with great unmet medical need. Nouscom has exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy, to Janssen Oncology. The program is under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms. Nouscom was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy. The company is backed by international life sciences investors: 5AM, Andera Partners, Bpifrance, EQT Life Sciences, Indaco Venture Partners, M Ventures, Panakes Partners, Revelation Partners, Versant Ventures, and XGen Ventures and has raised a total of $130M to date. For more information on Nouscom, please visit the company’s website at www.nouscom.com

Company Details

Employees
65
Address
Bäumleingasse 18, Bs,basel-City 4051,switzerland
Phone
41612011831
Email
in****@****com.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
BS, Basel-City
Looking for a particular Nouscom employee's phone or email?

Nouscom Questions

News

Nouscom Presents Positive Phase 2 Results of NOUS-209 - GlobeNewswire

Nouscom Presents Positive Phase 2 Results of NOUS-209 GlobeNewswire

Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy, at ESMO 2025 - Yahoo! Finance UK

Nouscom Presents Positive Phase 2 Results of NOUS-209 Immunotherapy Combined with Pembrolizumab in MSI-H Metastatic Colorectal Cancer Patients Refractory to Anti-PD-1 Therapy, at ESMO 2025 Yahoo! Finance UK

Nouscom reveals promising results for lynch syndrome immunotherapy - PharmaTimes

Nouscom reveals promising results for lynch syndrome immunotherapy PharmaTimes

The Pharma Letter Podcast — Episode 35 — Nouscom bets on dual vaccine strategy to outsmart cancer - The Pharma Letter

The Pharma Letter Podcast — Episode 35 — Nouscom bets on dual vaccine strategy to outsmart cancer The Pharma Letter

Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers - GlobeNewswire

Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers GlobeNewswire

Nouscom extends Series C round to $82m for cancer vaccine trials - Pharmaceutical Technology

Nouscom extends Series C round to $82m for cancer vaccine trials Pharmaceutical Technology

Eckhard Niemeier to head up business at Nouscom - The Pharma Letter

Eckhard Niemeier to head up business at Nouscom The Pharma Letter

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer - Frontiers

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer Frontiers

Tailored Cancer Vaccines? NousCom is working on it! - Labiotech.eu

Tailored Cancer Vaccines? NousCom is working on it! Labiotech.eu

$72 Million Funds Neoantigen-based Cancer Vaccine Candidates - Vax-Before-Travel

$72 Million Funds Neoantigen-based Cancer Vaccine Candidates Vax-Before-Travel

NousCom bags €42M to trial off-the-shelf cancer vaccine - Fierce Biotech

NousCom bags €42M to trial off-the-shelf cancer vaccine Fierce Biotech

Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer - GlobeNewswire

Nouscom’s Off-the-Shelf Neoantigen Immunotherapy, NOUS-209, Continues to Elicit Potent and Durable Immune Responses in Lynch Syndrome Carriers Highlighting its Potential to ‘Intercept’ Cancer GlobeNewswire

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines - Labiotech.eu

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines Labiotech.eu

European cancer vaccine startup Nouscom poaches Pfizer I-O executive - Fierce Biotech

European cancer vaccine startup Nouscom poaches Pfizer I-O executive Fierce Biotech

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round - GlobeNewswire

Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round GlobeNewswire

Nouscom - The Pharma Letter

Nouscom The Pharma Letter

Okairos vets boot up cancer I/O player Nouscom with $13M A round - Fierce Biotech

Okairos vets boot up cancer I/O player Nouscom with $13M A round Fierce Biotech

Nouscom to Present Updated Positive Data on NOUS-209’s - GlobeNewswire

Nouscom to Present Updated Positive Data on NOUS-209’s GlobeNewswire

Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines - GlobeNewswire

Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines GlobeNewswire

Nouscom Appoints Adrian Woolfson as CMO - European Biotechnology Magazine

Nouscom Appoints Adrian Woolfson as CMO European Biotechnology Magazine

After the field left her behind, a scientist-turned-investor gets her first R&D job; Nouscom finds new leadership for its cancer vaccines - Endpoints News

After the field left her behind, a scientist-turned-investor gets her first R&D job; Nouscom finds new leadership for its cancer vaccines Endpoints News

Biotech investment diversifies into cell therapies and immunology - drugdiscoverytrends.com

Biotech investment diversifies into cell therapies and immunology drugdiscoverytrends.com

Nouscom appoints COO and board members - PMLiVE

Nouscom appoints COO and board members PMLiVE

Top Nouscom Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant